Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia

Pain

Volumn 147, Issue 1-3, 2009, Pages 165-174

  Sakurai, Mariko ^a   Egashira, Nobuaki ^a   Kawashiri, Takehiro ^a   Yano, Takahisa ^a   Ikesue, Hiroaki ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Calcium magnesium; Cold hyperalgesia allodynia; Mechanical allodynia; Neuropathy; Oxalate; Oxaliplatin

Indexed keywords

ELPLAT; GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIC ACID; OXALIPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ACETONE TEST; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLD; COLD PLATE TEST; CONTROLLED STUDY; EXPERIMENTAL TEST; HYPERALGESIA; MALE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; VON FREY TEST;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CALCIUM; COLD TEMPERATURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; MAGNESIUM; MALE; NEURALGIA; ORGANOPLATINUM COMPOUNDS; OXALATES; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70449670357     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.09.003     Document Type: Article

References (39)

1. + channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (2000) 25-32
2. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 182 (2003) 12-20
3. + channels in frog peripheral myelinated axons. Gen Physiol Biophys 25 (2006) 263-276
4. Boughattas N.A., Hecquet B., Fournier C., Bruguerolle B., Trabelsi H., Bouzouita K., Omrane B., and Levi F. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos 15 (1994) 761-773
5. Cata J.P., Weng H.R., Lee B.N., Reuben J.M., and Dougherty P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72 (2006) 151-169
6. Cassidy J., and Misset J.L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29 (2002) 11-20
7. Cavaletti G., Tredici G., Petruccioli M.G., Donde E., Tredici P., Marmiroli P., Minoia C., Ronchi A., Bayssas M., and Etienne G.G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37 (2001) 2457-2463
8. de Gramont A., Vignoud J., and Tournigand C. Oxalipaltin/5FU/LV in adjuvant colon cancer: safety results of the international randomized MOSAIC trial. Prc Am Soc Clin Oncol 21 (2002) 132a
9. Desoiz B., and Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev in Oncol/Hematol 42 (2002) 317-325
10. Dieras V., Bougnoux P., Petit T., Chollet P., Beuzeboc P., Borel C., Husseini F., Goupil A., Kerbrat P., Misset J.L., Bensmaïne M.A., Tabah-Fisch I., and Pouillart P. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pre-treated ovarian cancer patients. Ann Oncol 13 (2002) 256-266
11. Donzelli E., Carfì M., Miloso M., Strada A., Galbiati S., Bayssas M., Griffon-Etienne G., Cavaletti G., Petruccioli M.G., and Tredici G. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol 67 (2004) 65-73
12. Egashira N., Iwasaki K., Takashima A., Watanabe T., Kawabe H., Matsuda T., Mishima K., Chidori S., Nishimura R., and Fujiwara M. Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. Brain Res 1059 (2005) 7-12
13. Egashira N., Tanoue A., Higashihara F., Mishima K., Fukue Y., Takano Y., Tsujimoto G., Iwasaki K., and Fujiwara M. V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci Lett 356 (2004) 195-198
14. Extra J.M., Marty M., Brienza S., and Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25 (1998) 13-22
15. Flatters S.J., and Bennett G.J. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109 (2004) 150-161
16. Gamelin L., Boisdron-Celle M., Delva R., Guerin-Meyer V., Ifrah N., Morel A., and Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fulorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 15 (2004) 4055-4061
17. Gamelin L., Boisdron-Celle M., Morel A., Poirier A.L., Berger V., Gamelin E., Tournigand C., and de Gramont A. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26 (2008) 1188-1189
18. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., and Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6 (2000) 1205-1218
19. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., and Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 (2001) 2293-2297
20. Hansen S.W., Helweg-Larsen S., and Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 7 (1989) 1457-1461
21. Hochster H.S., Grothey A., and Childs B.H. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25 (2007) 4028-4029
22. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., Wyrick S.D., and Chaney S.G. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46 (1998) 342-351
23. Ibrahim A., Hirschfeld S., Cohen M.H., Griebel D.J., Williams G.A., and Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 9 (2004) 8-12
24. Jamieson S.M., Liu J., Connor B., and McKeage M.J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56 (2005) 391-399
25. Kagiava A., Tsingotjidou A., Emmanouilides C., and Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 29 (2008) 1100-1106
26. Kiernan M.C. The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer 43 (2007) 2631-2633
27. Ling B., Authier N., Balayssac D., Eschalier A., and Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128 (2007) 225-234
28. Ling B., Coudoré-Civiale M.A., Balayssac D., Eschalier A., Coudoré F., and Authier N. Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology 234 (2007) 176-184
29. Louvet C., André T., Tigaud J.M., Gamelin E., Douillard J.Y., Brunet R., François E., Jacob J.H., Levoir D., Taamma A., Rougier P., Cvitkovic E., and de Gramont A. Phase II study of oxaliplatin, fluorouracil, and folic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20 (2002) 4543-4548
30. Luo F.R., Wyrick S.D., and Chaney S.G. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44 (1999) 29-38
31. McKeage M.J., Hsu T., Screnci D., Haddad G., and Baguley B.C. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85 (2001) 1219-1225
32. Nadal X., Banos J.E., Kieffer B.L., and Maldonado R. Neuropathic pain is enhanced in delta-opioid receptor knockout mice. Eur J Neurosci 23 (2006) 830-834
33. Pasetto L.M., D'Andrea M.R., Rossi E., and Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 59 (2006) 159-168
34. Petit T., Benider A., Yovine A., Bougnoux P., Spaeth D., Maindrault-Goebel F., Serin D., Tigaud J.D., Eymard J.C., Simon H., Bertaux B., Brienza S., and Cvitkovic E. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 17 (2006) 337-343
35. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 (2002) 9-17
36. Saif M.W., and Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1 (2005) 249-258
37. Ta L.E., Espeset L., Podratz J., and Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27 (2006) 992-1002
38. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., and Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 (2002) 1767-1774
39. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110